US Bancorp’s Prime Medicine PRME Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
– Sell
-33
Closed -$115 – 4310
2026
Q1
$115 Buy
+33
New +$126 ﹤0.01% 4125
2025
Q1
– Sell
-202
Closed -$590 – 4328
2024
Q4
$590 Buy
+202
New +$709 ﹤0.01% 4013
2023
Q4
– Sell
-346
Closed -$3.3K – 4111
2023
Q3
$3.3K Hold
346
– – ﹤0.01% 3553
2023
Q2
$5.07K Buy
+346
New +$4.83K ﹤0.01% 3473

Other funds holding PRME

US Bancorp's PRME Position: Q2 2026 in Review

US Bancorp sold out of Prime Medicine (PRME) in Q2 2026, closing a stake of 33 shares — an estimated $115 sold.

US Bancorp first reported a position in PRME in Q2 2023 and held it in 4 quarters. The position peaked at $5.07K in Q2 2023. 187 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • US Bancorp reported no remaining Prime Medicine position as of Q2 2026 after selling out during the quarter.
  • US Bancorp sold 33 Prime Medicine shares in Q2 2026, an estimated $115.
  • US Bancorp first reported a position in Prime Medicine in Q2 2023 and held it in 4 quarters.
  • US Bancorp's Prime Medicine position peaked at $5.07K in Q2 2023.
  • 187 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.